Section of Gastroenterology and HepatologyDepartment of Pediatrics Yale University School of Medicine New Haven CT Department of Statistics and Data Science Yale University New Haven CT Department of Pediatrics Yale University School of Medicine New Haven CT Transplant and Regenerative Medicine CenterHospital for Sick Kids University of Toronto Toronto ON Canada Icahn School of Medicine at Mount Sinai New York NY Children's Hospital Colorado and the University of Colorado School of Medicine Aurora CO Division of Pediatric Gastroenterology, Hepatology and Liver TransplantationAdventHealth for Children AdventHealth Transplant Institute Orlando FL Emory University School of Medicine Atlanta GA Division of Hepatology Holtz Children's HospitalUniversity of Miami Miami FL Department of PediatricsFeinberg School of Medicine Northwestern University Chicago IL Department of Radiology The Royal Marsden NHS Foundation Trust London UK MedStar Georgetown Transplant Institute Washington DC Hillman Center for Pediatric Transplantation Children's Hospital of Pittsburgh Pittsburgh PA.
Liver Transpl. 2022 May;28(5):819-833. doi: 10.1002/lt.26379. Epub 2022 Jan 30.
Biliary strictures affect 4%-12% of pediatric liver transplantations. Biliary strictures can contribute to graft loss if left untreated; however, there remains no consensus on the best course of treatment. Study objectives included analyses of outcomes associated with biliary stricture management strategies via percutaneous transhepatic cholangiography (PTC), endoscopic retrograde cholangiopancreatography (ERCP), or surgery. We identified pediatric liver transplantation recipients (2011-2016) with biliary strictures from the Society of Pediatric Liver Transplantation (SPLIT) registry and retrieved imaging, procedural, and operative reports from individual centers. Subanalyses were performed to specifically evaluate PTC and ERCP for "optimal biliary outcome" (OBO), defined as graft survival with stricture resolution and without recurrence or surgery. A total of 113 children with a median follow-up of 3.9 years had strictures diagnosed 100 days (interquartile range, 30-290) after liver transplantation; 81% were isolated anastomotic strictures. Stricture resolution was achieved in 92% within 101 days, more frequently with isolated anastomotic strictures (96%). 20% of strictures recurred, more commonly in association with hepatic artery thrombosis (32%). Patient and graft survival at 1 and 3 years were 99% and 98% and 94% and 92%, respectively. In a subgroup analysis of 79 patients with extrahepatic strictures managed by PTC/ERCP, 59% achieved OBO following a median of 4 PTC, and 75% following a median of 3 ERCP (P < 0.001). Among patients with OBO, those with ERCP had longer time intervals between successive procedures (41, 47, 54, 62, 71 days) than for PTC (27, 31, 36, 41, 48 days; P < 0.001). Allograft salvage was successful across all interventions. Stricture resolution was achieved in 92%, with 20% risk of recurrence. Resolution without recurrence was highest in patients with isolated anastomotic strictures and without hepatic artery thrombosis.
胆道狭窄影响 4%-12%的儿科肝移植患者。如果不进行治疗,胆道狭窄可能导致移植物丢失;然而,对于最佳治疗方案仍未达成共识。本研究的目的包括通过经皮经肝胆管造影术(PTC)、内镜逆行胰胆管造影术(ERCP)或手术分析胆道狭窄管理策略的相关结果。我们从小儿肝移植协会(SPLIT)注册处确定了 2011 年至 2016 年患有胆道狭窄的小儿肝移植受者,并从各个中心检索了影像学、程序和手术报告。进行了亚分析以专门评估 PTC 和 ERCP 对“最佳胆道结果”(OBO)的作用,定义为移植物存活、狭窄缓解且无复发或手术。共有 113 名儿童在中位随访 3.9 年后诊断为胆道狭窄,在肝移植后 100 天(四分位距 30-290)诊断;81%为孤立吻合口狭窄。92%的狭窄在 101 天内得到解决,孤立吻合口狭窄更常见(96%)。20%的狭窄复发,更常见于肝动脉血栓形成(32%)。1 年和 3 年的患者和移植物存活率分别为 99%和 98%,94%和 92%。在 79 例接受 PTC/ERCP 治疗的肝外胆道狭窄患者的亚组分析中,59%在中位数为 4 次 PTC 后达到 OBO,75%在中位数为 3 次 ERCP 后达到 OBO(P<0.001)。在达到 OBO 的患者中,ERCP 患者两次手术之间的时间间隔更长(41、47、54、62、71 天),而 PTC 为(27、31、36、41、48 天;P<0.001)。所有干预措施的移植物挽救均成功。92%的患者狭窄得到解决,20%的患者有复发风险。在孤立吻合口狭窄且无肝动脉血栓形成的患者中,无复发的狭窄缓解率最高。